From The Motley Fool · Motley Fool Transcribing · · 2m
Thermo Fisher Q3 2026 Earnings Beat
Thermo Fisher reports 9% revenue growth and 15% adjusted EPS surge as AI and end markets drive expansion.
In brief
Thermo Fisher reports 9% revenue growth and 15% adjusted EPS surge as AI and end markets drive expansion. Thermo Fisher's Q3 2026 results exceeded guidance with $12.14 billion revenue, 6% organic growth, and $6.68 adjusted EPS, fueled by strong pharma and biotech performance and AI integration. Originally reported by…
Q3 Results
Thermo Fisher reported $12.14 billion revenue, 9% year-over-year growth, and $6.68 adjusted EPS, 15% higher than prior year.
Organic Growth
Organic revenue grew 6% driven by strong pharma, biotech, and industrial end markets with flat academic and government performance.
Adjusted EPS
Adjusted EPS rose 15% to $6.68, reflecting strong operational execution and improved end-market conditions.
Tariff Refund Impact
Net tariff refund recovery of $60 million boosted adjusted operating income and $0.15 on adjusted EPS.
R&D Investment
R&D spending reached $350 million, 6.7% of manufacturing revenue, focused on high-impact innovation.
Microbiology Divestiture
Completed sale of microbiology business generated $1 billion in proceeds and reduced revenue by 1%.
AI Integration
AI-enabled software automates workflows in electron microscopy, reducing manual setup time by 90%.
Orbitrap Isora Launch
Orbitrap Isora mass spectrometer launched for isotope ratio analysis in environmental and life sciences research.
Ion 560 Chip
Ion 560 Chip launched for Ion GeneStudio S5 platform, providing nearly twice the sequencing capacity.
Precure Initiative
Precure initiative with Mayo Clinic uses proteomics and Orbitrap mass spectrometry for patient sample analysis.
AI-Automation Center
First AI-Automation Innovation Center opened in South Korea for customer collaboration on scientific workflows.
Full-Year Guidance
Full-year revenue guidance raised to $47.7 billion-$48.2 billion with 7%-8% growth over 2025.
Capital Deployment
Completed $1 billion microbiology divestiture and $4 billion share repurchases for 2026.
PPI Business System
PPI Business System enabled 120 basis points of adjusted operating margin expansion and strong earnings growth.
End Market Performance
Pharma and biotech grew high single digits, industrial and applied grew high single digits, diagnostics grew low single digits.
2026 Outlook
Thermo Fisher expects 10%-11% adjusted EPS growth and 4% organic revenue growth for full year 2026.
The key point
Thermo Fisher's Q3 2026 results exceeded guidance with $12.14 billion revenue, 6% organic growth, and $6.68 adjusted EPS, fueled by strong pharma and biotech performance and AI integration.
